Project Grant R21CA301104
- Federal Grant Award Summary The University of Pittsburgh received a $149,804 Project Grant from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398) awarded March 1, 2025, with completion scheduled for February 28, 2026. This award supports research investigating the impact of LAG3 (Lymphocyte Activation Gene 3) on CD8+ T cell motility and migration in the context of cancer immunotherapy. The research builds upon preliminary findings demonstrating that...
- Federal Grant Award Summary The University of Pittsburgh has received a $121,857 Project Grant from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398) effective August 1, 2025, through July 31, 2027. This award supports a K99/R00 Pathway to Independence research project investigating how anti-cancer drugs modulate T cell activity within the tumor microenvironment to overcome immune checkpoint blockade (ICB) resistance. The research delivers three integrated...
- Federal Grant Award Summary The University of Pittsburgh received a $408,829 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) effective June 1, 2025, through May 31, 2027. This award supports the development of positive allosteric modulators (PAMs) targeting XCR1, a chemokine receptor expressed on conventional dendritic cells subtype 1 (CDC1s). The research will utilize DNA-encoded library (DEL) technology and cryo-electron...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded the University of Pittsburgh a $151,040 Project Grant under the Cancer Research Manpower program (CFDA 93.398) on December 12, 2025, with a completion date of November 30, 2027. This award supports biomedical research training and career development in cancer research aligned with the National Cancer Program's strategic priorities. The grant funds research investigating the relative and synergistic contributions of...
- Federal Project Grant Award Summary The University of Pittsburgh received a $408,829 Project Grant from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396), effective September 1, 2025 through August 31, 2027. This award supports the development of an integrative framework for surface protein imputation in spatial biology applications. The project delivers machine learning (ML) methodologies and computational tools designed to predict surface protein abundance...
- Federal Grant Award Summary The National Cancer Institute awarded the University of Pittsburgh a $141,566 Project Grant on March 24, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support biomedical research training and career development in cancer research. The grant funds research focused on understanding the conformational landscape and regulation of small GTPases (SMGs), specifically examining how oncogenic RhoA proteins function in cancer cell environments. The project...
- Federal Grant Award Summary The National Cancer Institute awarded the University of Pittsburgh a $151,920 Project Grant under the Cancer Biology Research program (CFDA 93.396) effective September 1, 2025, through August 31, 2027. This award supports fundamental research to develop and validate Nuclear Magnetic Resonance (NMR) strategies for investigating allosteric inhibitor binding effects on Src-family kinases implicated in acute myeloid leukemia (AML). The research aims to characterize...
- Federal Project Grant Award Summary The University of Pittsburgh received a $261,662 Project Grant from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398), awarded December 1, 2025, with completion targeted for April 16, 2029. This award supports an integrated in silico and in vivo genetic screening research initiative designed to identify subtype-specific hepatocellular carcinoma (HCC) genetic dependencies. The project addresses a significant clinical...
- Federal Project Grant Award Summary The University of Pittsburgh received a $412,856 Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective May 1, 2026 through April 30, 2028. This award funds research investigating the role of cell cycle plasticity in bladder cancer growth and progression. The research will generate a systematic catalog of cell cycle heterogeneity across 661 bladder tumors using single-cell spatial proteomics...
- Federal Project Grant Award Summary Pennsylvania State University, doing business as Penn State Milton S. Hershey Medical Center, received a $166,800 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) effective August 1, 2025, through July 31, 2027. This award supports research to develop and evaluate improved methods for treating lung adenocarcinoma, specifically targeting SMARCA4-mutant lung adenocarcinoma through combination...
The University of Pittsburgh received a $408,829 Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), awarded March 13, 2026, with completion targeted for February 29, 2028. This award funds research investigating immunosuppression mediated by regulatory CD8+ T cells in lung cancers, with the objective of improving immunotherapy efficacy for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) patients. The project delivers fundamental research services aimed at characterizing how KIR+CD8+ T cells and their murine equivalent (Ly49+CD8+ T cells) contribute to immune evasion and resistance to checkpoint blockade therapies such as anti-PD-1 and anti-CTLA-4 antibodies. The research deliverables include profiling regulatory CD8+ T cells across different lung cancer subtypes using murine orthotopic lung cancer models and patient specimens, elucidating the cellular and molecular mechanisms by which these regulatory T cells suppress anti-tumor immunity, and testing therapeutic strategies to target these cells for enhanced immunotherapy response. This work directly supports the Cancer Biology Research program's mission to provide fundamental information on cancer mechanisms with the expectation of developing better prevention, detection, diagnosis, and treatment methods for neoplastic diseases, specifically addressing the significant unmet need of improving clinical outcomes for immunotherapy-resistant lung cancer patients.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $408.8k | 3/27/26 |